The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
 
Andrew X. Zhu
Consulting or Advisory Role - Eisai
 
Peter R. Galle
Honoraria - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Lilly; Sillajen
Consulting or Advisory Role - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Lilly; Sillajen
Speakers' Bureau - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Lilly; Sillajen
Research Funding - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Lilly; Sillajen
 
Masatoshi Kudo
No Relationships to Disclose
 
Richard S. Finn
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer (Inst)
 
Ling Yang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
Travel, Accommodations, Expenses - Lilly
 
Paolo Abada
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
Travel, Accommodations, Expenses - Lilly
 
Shao-Chun Chang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Josep M. Llovet
Honoraria - Bayer; Biocompatibles; Boehringer Ingelheim; Bristol-Myers Squibb; Celsion; Eisai; Genentech; GlaxoSmithKline; Guerbet; Lilly; Merck; Novartis; Roche
Consulting or Advisory Role - Bayer; Biocompatibles; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Celsion; Eisai; Genentech; GlaxoSmithKline; Guerbet; Lilly; Merck; Novartis; Roche
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst)